Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAUL GETZ

Allopathic & Osteopathic Physicians Dermatology

NPI
1508866443
CMS profile
249750
Location
WEST DUNDEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$888.03

32 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $874.03 31
Education $14.00 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAUL GETZ

NPI 1508866443 · CMS profile ID 249750

Allopathic & Osteopathic Physicians / Dermatology

WEST DUNDEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508866443?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAUL GETZ, NPI 1508866443, CMS profile ID 249750. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508866443?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). PAUL GETZ, NPI 1508866443, CMS profile ID 249750. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508866443?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
PAUL GETZ, NPI 1508866443, CMS profile ID 249750, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1508866443?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

32 matching records · $888.03 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 32 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–32 of 32.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $116.6612/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335855 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $6.7412/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051621183 CMS
UCB, Inc. $25.5711/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021481529 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $6.5711/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051621181 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $144.7011/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051621185 CMS
Dermavant Sciences, Inc. $179.5610/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991189689 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $7.3009/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051621179 CMS
ABBVIE INC. $6.8009/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335853 CMS
PFIZER INC. $10.4008/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050336871 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $6.7008/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051621177 CMS
UCB, Inc. $18.1407/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021481525 CMS
ABBVIE INC. $6.2607/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335851 CMS
E.R. Squibb & Sons, L.L.C. $16.2807/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014922173 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $6.2707/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051621175 CMS
ABBVIE INC. $5.7006/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335849 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $5.7906/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051621173 CMS
E.R. Squibb & Sons, L.L.C. $16.2805/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014922017 CMS
PFIZER INC. $3.3204/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049500346 CMS
E.R. Squibb & Sons, L.L.C. $13.0204/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014922009 CMS
PFIZER INC. $5.4604/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049667407 CMS
PFIZER INC. $5.8703/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049692825 CMS
ABBVIE INC. $6.5003/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335847 CMS
ABBVIE INC. $129.7303/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335845 CMS
PFIZER INC. $3.8503/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049408289 CMS
ABBVIE INC. $30.4103/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335843 CMS
Dermavant Sciences, Inc. $7.2403/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991189685 CMS
PFIZER INC. $5.2503/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049755529 CMS
Organogenesis Inc. $28.4802/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048146887 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.5602/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997131579 CMS
Incyte Corporation $16.1202/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044851523 CMS
ABBVIE INC. $7.5002/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997335841 CMS
Dermavant Sciences, Inc. $14.0001/26/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991189681 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,203.48 19
PY2020 $161.56 8
PY2021 $1,512.52 60
PY2022 $1,032.69 42
PY2023 $888.03 32
PY2024 $985.47 43
PY2025 $621.06 48

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,013.60 1
PY2025 Principal investigator $446,834.92 130
PY2024 Recipient $7,087.86 1
PY2024 Principal investigator $650,362.14 156
PY2023 Recipient $10,934.40 2
PY2023 Principal investigator $209,903.19 44
PY2022 Principal investigator $139,606.12 29
PY2021 Recipient $11,617.83 3
PY2021 Principal investigator $358,649.13 52
PY2020 Principal investigator $277,127.30 39
PY2019 Principal investigator $329,491.24 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

131 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $3,413.00 12/22/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area No dispute reported 06/30/2026 1175360603
Principal investigator 1 Incyte Corporation $3,852.00 12/19/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531386
Principal investigator 1 Incyte Corporation $1,058.20 12/08/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531405
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531425
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531437
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531441
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531444
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531457
Principal investigator 1 Incyte Corporation $4,586.30 11/26/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531364
Principal investigator 1 Incyte Corporation $3,486.60 11/26/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531376
Principal investigator 1 Incyte Corporation $4,834.80 11/26/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531380
Principal investigator 1 Incyte Corporation $2,277.90 11/24/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531432
Principal investigator 1 Incyte Corporation $4,095.00 11/06/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531371
Principal investigator 1 Incyte Corporation $16.18 11/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531390
Principal investigator 1 Incyte Corporation $2.12 11/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531393
Principal investigator 1 Incyte Corporation $135.40 11/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531398
Principal investigator 1 Incyte Corporation $34.35 11/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531402
Principal investigator 1 Incyte Corporation $8.22 11/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531409
Principal investigator 1 Incyte Corporation $8.22 11/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531412
Principal investigator 1 Incyte Corporation $8.22 11/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531416
Principal investigator 1 Incyte Corporation $8.22 11/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531421
Principal investigator 1 Incyte Corporation $24.68 11/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531448
Principal investigator 1 Incyte Corporation $124.54 11/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531451
Principal investigator 1 Janssen Research & Development, LLC $1,602.00 11/03/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175360568
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Dundee Dermatology
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235997589
Principal investigator 1 PFIZER INC. $2,132.00 10/04/2025 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228825635
Principal investigator 1 Incyte Corporation $1,652.40 10/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531360
Principal investigator 1 Incyte Corporation $250.00 10/01/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531357
Principal investigator 1 Incyte Corporation $6,694.20 09/23/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531307
Principal investigator 1 Janssen Research & Development, LLC $6,500.00 09/16/2025 Non-covered Recipient Entity
Dr. Paul Getz
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175215982
Principal investigator 1 Incyte Corporation $1,231.00 09/12/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531312
Principal investigator 1 Incyte Corporation $86.00 09/12/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531317
Principal investigator 1 Incyte Corporation $2,900.00 09/12/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531321
Principal investigator 1 Incyte Corporation $104.00 09/12/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531330
Principal investigator 1 Incyte Corporation $3,000.00 09/12/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531333
Principal investigator 1 Incyte Corporation $3,500.00 09/12/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531337
Principal investigator 1 Incyte Corporation $15,000.00 09/12/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531349
Principal investigator 1 Incyte Corporation $768.00 09/12/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531353
Principal investigator 1 Incyte Corporation $3,104.10 09/11/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531303
Principal investigator 1 Incyte Corporation $3,486.60 08/26/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531294
Principal investigator 1 Incyte Corporation $3,500.00 08/22/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531341
Principal investigator 1 Incyte Corporation $1,577.70 08/20/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531325
Principal investigator 1 Incyte Corporation $3,347.10 08/07/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531299
Principal investigator 1 Janssen Research & Development, LLC $1,817.00 08/04/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175360506
Principal investigator 1 Janssen Research & Development, LLC $2,444.00 08/01/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175360561
Principal investigator 1 Incyte Corporation $1,153.80 07/17/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531283
Principal investigator 1 Incyte Corporation $1,743.30 07/10/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531288
Principal investigator 1 Incyte Corporation $22.90 07/01/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531345
Principal investigator 1 Incyte Corporation $707.00 06/25/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531249
Principal investigator 1 Incyte Corporation $1,919.00 06/25/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531253
Principal investigator 1 Incyte Corporation $1,289.20 06/25/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531261
Principal investigator 1 Incyte Corporation $1,753.00 06/25/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531265
Principal investigator 1 Incyte Corporation $15,450.00 06/20/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531257
Principal investigator 1 Incyte Corporation $3,090.00 06/20/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531274
Principal investigator 1 Incyte Corporation $1,926.00 06/19/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531240
Principal investigator 1 Incyte Corporation $1,926.00 06/05/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531245
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,521.69 06/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190310420
Principal investigator 1 Incyte Corporation $576.90 05/27/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531236
Principal investigator 1 Janssen Research & Development, LLC $396.00 05/27/2025 Non-covered Recipient Entity
Dr. Paul Getz
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175215977
Principal investigator 1 Janssen Research & Development, LLC $16,726.00 05/27/2025 Non-covered Recipient Entity
Dr. Paul Getz
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175215998
Principal investigator 1 Janssen Research & Development, LLC $3,170.00 05/26/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175360595
Principal investigator 1 Janssen Research & Development, LLC $2,838.00 05/09/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175360539
Principal investigator 1 Incyte Corporation $1,153.80 05/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531231
Principal investigator 1 Eli Lilly and Company $18,869.34 04/29/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187890430
Principal investigator 1 Janssen Research & Development, LLC $3,745.00 04/28/2025 Non-covered Recipient Entity
Dr. Paul Getz
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175215971
Principal investigator 1 Amgen Inc. $14,000.00 04/23/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) No dispute reported 06/30/2026 1246646378
Principal investigator 1 Amgen Inc. $24,897.00 04/23/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246646383
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,500.00 04/15/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1190310418
Principal investigator 1 Incyte Corporation $3,000.00 04/10/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531207
Principal investigator 1 Incyte Corporation $1,926.00 04/10/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531211
Principal investigator 1 Incyte Corporation $3,500.00 04/10/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531219
Principal investigator 1 Incyte Corporation $15,000.00 04/10/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531222
Principal investigator 1 Incyte Corporation $1,500.00 04/10/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531227
Principal investigator 1 Incyte Corporation $2,423.70 04/09/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531269
Principal investigator 1 Incyte Corporation $576.90 04/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531215
Principal investigator 1 Incyte Corporation $12.36 04/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531279
Principal investigator 1 Janssen Research & Development, LLC $1,859.00 03/24/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175360587
Principal investigator 1 Incyte Corporation $3,043.80 03/20/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531046
Principal investigator 1 Janssen Research & Development, LLC $43,316.00 03/20/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175360515
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,685.48 03/15/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190302597
Principal investigator 1 Incyte Corporation $3,620.70 03/14/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531041
Principal investigator 1 Janssen Research & Development, LLC $2,253.00 03/14/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175360531
Principal investigator 1 Incyte Corporation $1,707.30 03/12/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531185
Principal investigator 1 Janssen Research & Development, LLC $46,487.00 03/07/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175360522
Principal investigator 1 Janssen Research & Development, LLC $38,468.00 03/07/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175360547
Principal investigator 1 Janssen Research & Development, LLC $3,404.00 03/06/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175360577
Principal investigator 1 Incyte Corporation $59.13 03/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531111
Principal investigator 1 Incyte Corporation $62.27 03/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531118
Principal investigator 1 Incyte Corporation $54.76 03/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531123
Principal investigator 1 Incyte Corporation $68.70 03/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531127
Principal investigator 1 Incyte Corporation $135.40 03/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531137
Principal investigator 1 Incyte Corporation $64.72 03/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531141
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531145
Principal investigator 1 Incyte Corporation $49.36 03/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531149
Principal investigator 1 Incyte Corporation $14.84 03/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531152
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531190
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531194
Principal investigator 1 Incyte Corporation $49.32 03/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531198
Principal investigator 1 Janssen Research & Development, LLC $3,874.00 03/03/2025 Non-covered Recipient Entity
Dr. Paul Getz
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175215992
Principal investigator 1 Janssen Research & Development, LLC $2,627.00 02/07/2025 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175360554
Principal investigator 1 Incyte Corporation $3,043.80 02/06/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531469
Principal investigator 1 Incyte Corporation $576.90 01/29/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531462
Principal investigator 1 Amgen Inc. $6,514.34 01/21/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246640969
Recipient E.R. Squibb & Sons, L.L.C. $9,013.60 01/17/2025 Covered Recipient Physician Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1236002257
Principal investigator 1 Incyte Corporation $1,707.30 01/15/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531170
Principal investigator 1 Novartis Pharmaceuticals Corporation $149.47 01/15/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1190302595
Principal investigator 1 Incyte Corporation $1,926.00 01/03/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240531465
Principal investigator 1 Incyte Corporation $307.40 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531050
Principal investigator 1 Incyte Corporation $90.10 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531054
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531057
Principal investigator 1 Incyte Corporation $201.40 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531061
Principal investigator 1 Incyte Corporation $275.60 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531065
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531070
Principal investigator 1 Incyte Corporation $10.60 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531073
Principal investigator 1 Incyte Corporation $14.58 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531077
Principal investigator 1 Incyte Corporation $53.80 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531081
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531085
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531088
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531093
Principal investigator 1 Incyte Corporation $90.10 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531098
Principal investigator 1 Incyte Corporation $74.20 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531101
Principal investigator 1 Incyte Corporation $135.40 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531106
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531114
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531132
Principal investigator 1 Incyte Corporation $43.04 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531157
Principal investigator 1 Incyte Corporation $43.04 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531161
Principal investigator 1 Incyte Corporation $124.54 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531165
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531174
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531176
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531181
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240531202